Resverlogix Corporation Announces Research Advances in Ophthalmology

CALGARY, ALBERTA -- (MARKET WIRE) -- May 09, 2007 -- Resverlogix Corp. ("Resverlogix") (TSX: RVX) is pleased to announce today that the research it sponsors in the laboratory of Dr. M. Francesca Cordeiro, Reader at UCL Institute of Ophthalmology (IoO), University College London and Hon. Consultant Ophthalmologist Western Eye Hospital, London, was presented in a poster during the 2007 Annual Meeting for the Association for Research Vision and Ophthalmology. One of the most interesting findings of this research is that it has demonstrated a successful method and route of delivery for a potential therapeutic to select cells in the back of the eye. These findings will be used for testing and development of Resverlogix's TGF-Beta Shield™ technology.